Depression, selective serotonin re-uptake inhibitors and the regulation of bone mass

IBMS BoneKEy ◽  
2009 ◽  
Vol 6 (1) ◽  
pp. 8-15 ◽  
Author(s):  
Itai Bab ◽  
Raz Yirmiya
Keyword(s):  
Bone Mass ◽  
Selective Serotonin ◽  
Uptake Inhibitors

Selective Serotonin Re-Uptake Inhibitors and Hyponatremia in Acutely Medically-Ill Inpatients

2016 ◽  
Vol 11 (2) ◽  
pp. 121-127 ◽  
Author(s):  
Saeid Noohi ◽  
André Do ◽  
Dominique Elie ◽  
Artin A. Mahdanian ◽  
Ching Yu ◽  
...  
Keyword(s):  
Selective Serotonin ◽  
Medically Ill ◽  
Uptake Inhibitors

Obsessive—Compulsive Disorder as a 5-HT Subsystem-Related Behavioural Disorder

1989 ◽  
Vol 155 (S8) ◽  
pp. 15-24 ◽  
Author(s):  
D. L. Murphy ◽  
J. Zohar ◽  
C. Benkelfat ◽  
M. T. Pato ◽  
T. A. Pigott ◽  
...  
Keyword(s):  
Obsessive Compulsive Disorder ◽  
Serotonin Uptake ◽  
Selective Serotonin ◽  
Therapeutic Effects ◽  
Obsessive Compulsive ◽  
Neurotransmitter System ◽  
Compulsive Disorder ◽  
Uptake Inhibitors ◽  
Anxiety Depression ◽  
Abnormal Brain

Involvement of the brain serotonin (5-HT) neurotransmitter system in obsessive-compulsive disorder (OCD) was originally suggested on the basis of therapeutic effects found with the semi-selective serotonin uptake inhibitor, clomipramine. More recent studies directly comparing clomipramine with non-selective or norepinephrine-selective uptake inhibitors, such as desipramine or nortriptyline, as well as studies with new, more selective serotonin uptake inhibitors, including fluvoxamine and fluoxetine, have supported that hypothesis. Clomipramine's antiobsessional effect has been augmented with the serotonin precursor, L-tryptophan, or with lithium, which has prominent serotonergic effects. Patients whose OCD symptoms improved on clomipramine worsened when the drug was discontinued (regardless of duration of therapy) and improved when clomipramine was reinstituted. OCD symptoms also worsened when metergoline, a 5-HT antagonist, was given to patients who had improved with clomipramine. Metergoline given alone had no effect. Administration of m-chlorophenylpiperazine (m-CPP), a 5-HT receptor agonist, to untreated OCD patients increased their anxiety, depression, and dysphoria, and exacerbated their OC symptoms. After 4 months of clomipramine therapy, m-CPP failed to produce the same behavioural effects, suggesting an alteration of a 5-HT subsystem (possibly downregulation of some 5-HT receptors). The data reviewed suggest an important role for an abnormal brain 5-HT subsystem in patients with OCD.

PW01-46 - Do selective serotonin re-uptake inhibitors modulate experimental panic elicited by cholecystokinin-tetrapeptide in healthy man?

2010 ◽  
Vol 25 ◽  
pp. 1465
Author(s):  
M. Kellner ◽  
C. Muhtz ◽  
C. Demiralay ◽  
J. Husemann ◽  
W. Koelsch ◽  
...  
Keyword(s):  
Selective Serotonin ◽  
Uptake Inhibitors ◽  
Healthy Man

New indole derivatives as potent and selective serotonin uptake inhibitors. [Erratum to document cited in CA119(2):8726n]

1993 ◽  
Vol 36 (15) ◽  
pp. 2242-2242 ◽  
Author(s):  
Jean Luc Malleron ◽  
Claude Gueremy ◽  
Serge Mignani ◽  
Jean Francois Peyronel ◽  
Alain Truchon ◽  
...  
Keyword(s):  
Serotonin Uptake ◽  
Selective Serotonin ◽  
Indole Derivatives ◽  
Serotonin Uptake Inhibitors ◽  
Uptake Inhibitors

Withdrawal Reactions Associated with Venlafaxine

1998 ◽  
Vol 32 (2) ◽  
pp. 291-294 ◽  
Author(s):  
Gordon Parker ◽  
Jenny Blennerhassett
Keyword(s):  
Single Dose ◽  
Side Effects ◽  
Clinical Picture ◽  
Withdrawal Syndrome ◽  
Withdrawal Symptoms ◽  
Selective Serotonin ◽  
Short Acting ◽  
Severe Withdrawal ◽  
Uptake Inhibitors

Objective: The aim of this paper is to describe discontinuation syndromes associated with abrupt and tapered withdrawal of venlafaxine, and to document that withdrawal symptoms may occur after missing a single dose. Clinical picture: We report on two patients prescribed venlafaxine. One developed a broad range of serious side effects after reaching a dose of 300 mg a day, and a severe withdrawal syndrome (including hallucinations) during a slow taper regime. The second had severe discontinuation symptoms during and aborting a slow taper regime, and described withdrawal responses after missing a single dose of venlafaxine. Conclusions: As for the short-acting selective serotonin re-uptake inhibitors, severe discontinuation reactions may occur with venlafaxine, seemingly marked most distinctly by headache, nausea, fatigue, dizziness and dysphoria, and may make cessation of the drug extremely difficult. Two strategies for addressing the concern are considered.

Sign in / Sign up

Export Citation Format

Share Document